Evidence map›Paper›PMID 31843808›Full record

ArticleNeurology2020

Survival time tool to guide care planning in people with dementia.

Miriam L Haaksma, Maria Eriksdotter, Debora Rizzuto, Jeannie-Marie S Leoutsakos, Marcel G M Olde Rikkert, René J F Melis, Sara Garcia-Ptacek

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Neurology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Article
  6. Observational
  7. Observational
  8. Survival rates in frontotemporal dementia and Alzheimer's disease.Neurodegenerative disease management · 2025
    Article
  9. Article
  10. Article
  11. Article
  12. Factors Associated With Alzheimer's Dementia Diagnosis and Survival in Down Syndrome.Journal of intellectual disability research : JIDR · 2025
    Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

  • Commented on by
    2020
5 · Who and what money

Authors and funding

7 authors.

Miriam L HaaksmaFrom the Department of Geriatric Medicine (M.L.H., M.G.M.O.R., R.J.F.M.), Radboudumc Alzheimer Center, Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, the Netherlands; Aging Research Center (M.L.H., D.R.), Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Solna; Division of Clinical Geriatrics (M.E., S.G.-P.), Department of Neurobiology, Care Sciences and Society, Karolinska Institutet; Theme Aging (M.E., S.G.-P.), Karolinska University Hospital, Huddinge, Sweden; Department of Psychiatry (J.-M.S.L.), Division of Geriatric Psychiatry and Neuropsychiatry, Johns Hopkins University School of Medicine, Baltimore, MD; Radboud University Medical Center (M.G.M.O.R.), Donders Institute for Brain, Cognition and Behaviour, Department of Geriatric Medicine, Radboudumc Alzheimer Center, Nijmegen, the Netherlands; and Department of Internal Medicine (S.G.-P.), Section for Neurology, Södersjukhuset Stockholm, Sweden.
Maria EriksdotterFrom the Department of Geriatric Medicine (M.L.H., M.G.M.O.R., R.J.F.M.), Radboudumc Alzheimer Center, Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, the Netherlands; Aging Research Center (M.L.H., D.R.), Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Solna; Division of Clinical Geriatrics (M.E., S.G.-P.), Department of Neurobiology, Care Sciences and Society, Karolinska Institutet; Theme Aging (M.E., S.G.-P.), Karolinska University Hospital, Huddinge, Sweden; Department of Psychiatry (J.-M.S.L.), Division of Geriatric Psychiatry and Neuropsychiatry, Johns Hopkins University School of Medicine, Baltimore, MD; Radboud University Medical Center (M.G.M.O.R.), Donders Institute for Brain, Cognition and Behaviour, Department of Geriatric Medicine, Radboudumc Alzheimer Center, Nijmegen, the Netherlands; and Department of Internal Medicine (S.G.-P.), Section for Neurology, Södersjukhuset Stockholm, Sweden.
Debora RizzutoFrom the Department of Geriatric Medicine (M.L.H., M.G.M.O.R., R.J.F.M.), Radboudumc Alzheimer Center, Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, the Netherlands; Aging Research Center (M.L.H., D.R.), Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Solna; Division of Clinical Geriatrics (M.E., S.G.-P.), Department of Neurobiology, Care Sciences and Society, Karolinska Institutet; Theme Aging (M.E., S.G.-P.), Karolinska University Hospital, Huddinge, Sweden; Department of Psychiatry (J.-M.S.L.), Division of Geriatric Psychiatry and Neuropsychiatry, Johns Hopkins University School of Medicine, Baltimore, MD; Radboud University Medical Center (M.G.M.O.R.), Donders Institute for Brain, Cognition and Behaviour, Department of Geriatric Medicine, Radboudumc Alzheimer Center, Nijmegen, the Netherlands; and Department of Internal Medicine (S.G.-P.), Section for Neurology, Södersjukhuset Stockholm, Sweden.
Jeannie-Marie S LeoutsakosFrom the Department of Geriatric Medicine (M.L.H., M.G.M.O.R., R.J.F.M.), Radboudumc Alzheimer Center, Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, the Netherlands; Aging Research Center (M.L.H., D.R.), Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Solna; Division of Clinical Geriatrics (M.E., S.G.-P.), Department of Neurobiology, Care Sciences and Society, Karolinska Institutet; Theme Aging (M.E., S.G.-P.), Karolinska University Hospital, Huddinge, Sweden; Department of Psychiatry (J.-M.S.L.), Division of Geriatric Psychiatry and Neuropsychiatry, Johns Hopkins University School of Medicine, Baltimore, MD; Radboud University Medical Center (M.G.M.O.R.), Donders Institute for Brain, Cognition and Behaviour, Department of Geriatric Medicine, Radboudumc Alzheimer Center, Nijmegen, the Netherlands; and Department of Internal Medicine (S.G.-P.), Section for Neurology, Södersjukhuset Stockholm, Sweden.
Marcel G M Olde RikkertFrom the Department of Geriatric Medicine (M.L.H., M.G.M.O.R., R.J.F.M.), Radboudumc Alzheimer Center, Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, the Netherlands; Aging Research Center (M.L.H., D.R.), Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Solna; Division of Clinical Geriatrics (M.E., S.G.-P.), Department of Neurobiology, Care Sciences and Society, Karolinska Institutet; Theme Aging (M.E., S.G.-P.), Karolinska University Hospital, Huddinge, Sweden; Department of Psychiatry (J.-M.S.L.), Division of Geriatric Psychiatry and Neuropsychiatry, Johns Hopkins University School of Medicine, Baltimore, MD; Radboud University Medical Center (M.G.M.O.R.), Donders Institute for Brain, Cognition and Behaviour, Department of Geriatric Medicine, Radboudumc Alzheimer Center, Nijmegen, the Netherlands; and Department of Internal Medicine (S.G.-P.), Section for Neurology, Södersjukhuset Stockholm, Sweden.
René J F MelisFrom the Department of Geriatric Medicine (M.L.H., M.G.M.O.R., R.J.F.M.), Radboudumc Alzheimer Center, Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, the Netherlands; Aging Research Center (M.L.H., D.R.), Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Solna; Division of Clinical Geriatrics (M.E., S.G.-P.), Department of Neurobiology, Care Sciences and Society, Karolinska Institutet; Theme Aging (M.E., S.G.-P.), Karolinska University Hospital, Huddinge, Sweden; Department of Psychiatry (J.-M.S.L.), Division of Geriatric Psychiatry and Neuropsychiatry, Johns Hopkins University School of Medicine, Baltimore, MD; Radboud University Medical Center (M.G.M.O.R.), Donders Institute for Brain, Cognition and Behaviour, Department of Geriatric Medicine, Radboudumc Alzheimer Center, Nijmegen, the Netherlands; and Department of Internal Medicine (S.G.-P.), Section for Neurology, Södersjukhuset Stockholm, Sweden.
Sara Garcia-PtacekFrom the Department of Geriatric Medicine (M.L.H., M.G.M.O.R., R.J.F.M.), Radboudumc Alzheimer Center, Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, the Netherlands; Aging Research Center (M.L.H., D.R.), Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Solna; Division of Clinical Geriatrics (M.E., S.G.-P.), Department of Neurobiology, Care Sciences and Society, Karolinska Institutet; Theme Aging (M.E., S.G.-P.), Karolinska University Hospital, Huddinge, Sweden; Department of Psychiatry (J.-M.S.L.), Division of Geriatric Psychiatry and Neuropsychiatry, Johns Hopkins University School of Medicine, Baltimore, MD; Radboud University Medical Center (M.G.M.O.R.), Donders Institute for Brain, Cognition and Behaviour, Department of Geriatric Medicine, Radboudumc Alzheimer Center, Nijmegen, the Netherlands; and Department of Internal Medicine (S.G.-P.), Section for Neurology, Södersjukhuset Stockholm, Sweden. saragptacek@gmail.com.

Funding

Research Education ComponentP30AG066507 · NIA · JOHNS HOPKINS UNIVERSITY · PI MARILYN S. ALBERT · 2020 to 2026
$29.3M
NIA NIH HHS P30 AG066507
6 · The paper itself

Abstract

objectiveTo develop survival prediction tables to inform physicians and patients about survival probabilities after the diagnosis of dementia and to determine whether survival after dementia diagnosis can be predicted with good accuracy.

methodsWe conducted a nationwide registry-linkage study including 829 health centers, i.e., all memory clinics and ≈75% of primary care facilities, across Sweden. Data including cognitive function from 50,076 people with incident dementia diagnoses ≥65 years of age and registered with the Swedish Dementia Register in 2007 to 2015 were used, with a maximum follow-up of 9.7 years for survival until 2016. Sociodemographic factors, comorbidity burden, medication use, and dates of death were obtained from nationwide registries. Cox proportional hazards regression models were used to create tables depicting 3-year survival probabilities for different risk factor profiles.

resultsBy August 2016, 20,828 (41.6%) patients in our cohort had died. Median survival time from diagnosis of dementia was 5.1 (interquartile range 2.9-8.0) years for women and 4.3 (interquartile range 2.3-7.0) years for men. Predictors of mortality were higher age, male sex, increased comorbidity burden and lower cognitive function at diagnosis, a diagnosis of non-Alzheimer dementia, living alone, and using more medications. The developed prediction tables yielded c indexes of 0.70 (95% confidence interval [CI] 0.69-0.71) to 0.72 (95% CI 0.71-0.73) and showed good calibration.

conclusionsThree-year survival after dementia diagnosis can be predicted with good accuracy. The survival prediction tables developed in this study may aid clinicians and patients in shared decision-making and advance care planning.

Indexed as

Decision Making, SharedPatient Care PlanningSurvival RateAdvance Care PlanningAgedAged, 80 and overAge FactorsAlzheimer DiseaseComorbidityDementiaFemaleHumansMalePrognosisProportional Hazards ModelsResidence Characteristics

Identifiers

PMID31843808
PMCPMC7080282

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.